• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

CSU investigates novel radiation drug technique

August 1, 2006

Fort Collins, Colo. - Colorado State University (CSU) researchers have developed a way to deliver intravenous radiation drugs to bone cancer patients without causing damage to other healthy cells and vital organs, drastically reducing illness and other common side effects of toxic radiation treatments, the university reports.

FORT COLLINS, COLO. — Colorado State University (CSU) researchers have developed a way to deliver intravenous radiation drugs to bone cancer patients without causing damage to other healthy cells and vital organs, drastically reducing illness and other common side effects of toxic radiation treatments, the university reports.

"The results of this study could change the standard of care for bone cancer patients — humans and dogs," says Dr. Nicole Ehrhart, a veterinary oncologist at CSU's veterinary college.

The technique also allows doctors to deliver radiation in only one dose in a higher, more effective concentration.

By isolating and separating circulating blood to the area of the tumor through a heart-lung machine while delivering radioactive drugs, doctors at the university's Animal Cancer Center deliver higher radiation doses to only the tumor while protecting vital organs and healthy tissues.

Advertisement

The doctors are working to pinpoint a dose that will achieve 90 percent or higher tumor kill in their canine patients; the goal for traditional treatments in people also is 90 percent tumor die-off before surgery.

"While most osteosarcoma patients don't receive radiation treatment," Earhart says, "we believe that, when delivered with this method that allows doctors to isolate the dose to the tumor, radiation treatment is very effective. In dogs, we know that using radiation in combination with chemotherapy increases our success over just one or the other treatments used alone."

The technique also allows clinicians the potential to add other drugs to bone tumor treatment that may typically be avoided because of their toxicity when applied to the entire body.

At the Animal Cancer Center, Ehrhart and other researchers have isolated the blood supply to a limb using special catheters and tourniquets, and circulated blood from that limb through a heart-lung machine. The radiation drug is delivered into the isolated blood supply, saving the healthy bone marrow in the rest of the patient's body from exposure to radiation. Once the radiation drugs reach the tumor, it is flushed from the system and the heart-lung machine is removed, allowing normal blood flow to return.

Results of the study show that because the technique allows higher doses of radiation directly to tumors, the dogs, who are patients at the Animal Cancer Center and participate in the study with their owners' consent, have few side effects, and early results show that the tumor die-off is significant.

The study uses a radiation drug called samarium, which is mixed with a special substance that causes the radioactive drug to bind to mineral in bones. The sticky substance allows the radiation to release into bone tumors. The benefit of the drug is that it is attracted to bone tumors because these tumors help spur bone growth at a more active rate. The drawback is the substance does adhere to healthy bone as well, causing damage to healthy tissue.

Bone cancer is a common diagnosis in large dogs and humans, particularly in children. Colorado State's Animal Cancer Center diagnoses and cares for 150 new cases of canine osteosarcoma every year. Typical treatment is removing the tumor and replacing the bone with a rod or amputating the limb. Most patients received chemotherapy before and after surgery to prevent the cancer from spreading.

Children who receive samarium treatment to their entire body often must have bone marrow transplants because of the extensive damage the radiation does to healthy bone marrow. Radiation therapy is typically not a standard treatment for people with osteosarcoma because of its toxic side effects, but it can kill tumor growth, stall progression and improve quality of life.

The study is funded by M.D. Anderson Cancer Center, the Limb Preservation Foundation in Denver and the Animal Cancer Center.

Related Content:

MedicalEducation
Performing and calculating a PCV
Performing and calculating a PCV
Brief overview of acid-base interpretation
Brief overview of acid-base interpretation
Texas Tech faculty member to inspire future rural veterinarians
Texas Tech faculty member to inspire future rural veterinarians

Advertisement

Latest News

What's new with the "Dentistry Lane" across the veterinary profession?

Meet the BlackDVM Network

Study finds certain canine breeds should be screened for cancer at young ages

AVMA releases 2 videos informing pet parents on pet dental care

View More Latest News
Advertisement